Browsing by Author "Lucero, Yalda"
Now showing 1 - 5 of 5
Results Per Page
Sort Options
- ItemAdaptation to the reality of Latin America of the Naspghan/Espghan 2016 guidelines on the diagnosis, prevention, and treatment of helicobacter pylori infection in pediatrics(2021) Harris D., Paul R.; Lucero, Yalda; Pierre, Reinaldo
- ItemAntimicrobial Resistance of Helicobacter pylori Isolated From Latin American Children and Adolescents (2008–2023): A Systematic Review(2024) Cabrera, Camila; Torres, Joaquín; Serrano Honeyman, Carolina Andrea; Gallardo, Paulina; Orellana, Vicente; George, Sergio; O'Ryan, Miguel; Lucero, YaldaBackground: Latin America has a high prevalence of Helicobacter pylori in children that may lead to peptic ulcer disease andeventually gastric cancer in adulthood. Successful eradication is hindered by rising antimicrobial resistance. We summarize H.pylori resistance rates in Latin American children from 2008 to 2023.Material and Methods: Systematic review following PRISMA guidelines and National Heart, Lung, and Blood Institute check-list to assess risk of bias (PROSPERO CRD42024517108) that included original cross-sectional observational studies reportingresistance to commonly used antibiotics in Latin American children and adolescents. We searched in PubMed, LILACS, andSciELO databases.Results: Of 51 studies, 45 were excluded. The quality of the six analyzed studies (297 H. pylori-positive samples) was satisfactory.Phenotypic methods (N = 3) reported higher resistance rates than genotypic studies (N = 3). Clarithromycin resistance rangedfrom 8.0% to 26.7% (6 studies; 297 samples), metronidazole from 1.9% to 40.2% (4 studies; 211 samples), amoxicillin from 0% to10.4% (3 studies; 158 samples), tetracycline resistance was not detected (3 studies; 158 samples), and levofloxacin resistance was2.8% (1 study; 36 samples).Conclusion: Scarce Latin American studies on H. pylori resistance, along with methodological heterogeneity, hinder conclusivefindings. Clarithromycin and metronidazole (first-line drugs) resistance is worrisome, likely impacting lower eradication rates.Urgent systematic surveillance or individual testing before treatment is necessary to enhance eradication.
- ItemHelicobacter pylori Infection Is Associated with Decreased Expression of SLC5A8, a Cancer Suppressor Gene, in Young Children(2016) Orellana Manzano, Andrea; O’Ryan, Miguel G.; Lagomarcino, Anne J.; George, Sergio; Muñoz, Mindy S.; Mamani, Nora; Serrano Honeyman, Carolina; Harris D., Paul R.; Ramilo, Octavio; Mejías, Asunción; Torres, Juan P.; Lucero, Yalda; Quest, Andrew F. G.; Orellana Manzano, Andrea; O’Ryan, Miguel G.; Lagomarcino, Anne J.; George, Sergio; Muñoz, Mindy S.; Mamani, Nora; Serrano Honeyman, Carolina; Harris D., Paul R.; Ramilo, Octavio; Mejías, Asunción; Torres, Juan P.; Lucero, Yalda; Quest, Andrew F. G.
- ItemPredominance of Rotavirus G8P[8] in a City in Chile, a Country Without Rotavirus Vaccination(2018) Lucero, Yalda; O'Ryan, Miguel; Liparoti, Giulia; Huerta, Nicole; Mamani, Nora; Ramani, Sasirekha; Lagomarcino, Anne J.; Del Canto, Felipe; Qüense, Jorge
- ItemRotavirus genotypes in children with gastroenteritis assisted in two public hospitals from Chile: viral strains circulating in a country without a universal vaccination against rotavirus(SOC CHILENA INFECTOLOGIA, 2012) Lucero, Yalda; Mamani, Nora; Cortes, Hector; Pena, Alfredo; Vergara, Rodrigo; O'Ryan, MiguelBackground: Rotavirus is the main cause of severe gastroenteritis (GE) in children. Two vaccines currently available have proven efficacy against the predominant genotypes. Rotavirus genotypes vary both geographically and/or temporally. Genotype surveillance is important to monitor trends associated or not with vaccine use. Aim: To update information on rotavirus genotypes circulating in two main cities of Chile. Methodology: Between May 2009-March 2010, children < 5y of age receiving medical care for GE in two large hospitals were recruited; none of these children had received rotavirus vaccine previously. Epidemiological information was recorded in an ad-hoc form and stool samples were collected for rotavinis detection by a commercial ELISA. Genotyping was performed by semi-nested RT-PCR. Results: A total of 296/967 samples (31%) were positive for rotavirus, with a peak in November/December mostly in children 7-24 months old (67%). G9P[8] was the predominant genotype (76%), followed for G1P[8] (6%) and G2P[4] (6%) in both cities. Conclusions: Rotavirus caused one third of GE requiring emergency room care and/or hospitalization, mostly in children within an age range susceptible to benefit from rotavirus vaccines. G9P[8], a genotype against which rotavirus vaccines have demonstrated high efficacy, was by far the most frequent rotavirus variant. Continued surveillance in Chile is crucial for providing background information on disease burden and strain diversity before the introduction of rotavirus vaccines.